Exhibit 10.8

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

AGREEMENT

THIS AGREEMENT is made effective as of the 17th day of October, 2003, between
IDEXX Europe B.V., a corporation organized under the law of The Netherlands
whose principal place of business is at Koolhovenlaan 20, 1119 NE -
Schiphol-Rijk, The Netherlands (“IDEXX”) and Ortho-Clinical Diagnostics, Inc., a
New York corporation with offices at 100 Indigo Creek Drive, Rochester, New
York, U.S.A. (“OCD”), and amends and restates the supply agreement effective as
of January 1, 1999 between IDEXX and OCD (the “Prior Europe Agreement”).

WHEREAS, OCD has been a supplier of analyzers for human applications and dry
slides, and IDEXX has been a supplier of analyzers for animal applications; and

WHEREAS, OCD and IDEXX Operations, Inc. (“IDEXX US”) have entered into an
agreement in the United States (the “US Agreement”) to (a) combine certain of
their respective skills and intellectual property and to invest significant
capital to create a New Analyzer (as defined below) and related panel holder
design for animal applications, which is expected to provide a superior analyzer
offering to customers, expand the sales of OCD dry slides and IDEXX analyzers,
and make IDEXX products more competitive and (b) ensure IDEXX US a continuing
supply of Dry Slides necessary for its continued sale of analyzers, including
the New Analyzer; and

WHEREAS, in the United States and in the Territory (as defined herein) different
market conditions as well as regulatory differences prevail, for which reasons
OCD and IDEXX desire to enter into a separate agreement for the supply of Dry
Slides in the European market and the other regions in the Territory; and as is
the case with the US Agreement, OCD and IDEXX desire to reflect herein their
mutual investments and exchange of know-how in connection with the supply of Dry
Slides as well as their desire to enter into new arrangements for the supply of
diagnostic slides and analyzers for Europe and the other regions in the
Territory, the terms and conditions of which are documented herein;

NOW THEREFORE, the parties hereby agree as follows:

 

--------------------------------------------------------------------------------

 

1.   DEFINITIONS

In this Agreement the following expressions shall have the meaning set opposite
them.

      “Agreements”   This Agreement and the US Agreement.       “Analyzers”  
The VETTEST Analyzer and the New Analzyer.       “Commencement Date”  
October 17, 2003.       “Dry Slide”   A chemical composition, comprising a
layered, coated dry film, specifically formulated to analyze for a body
constituent, which composition is immediately hydrated by any undiluted bodily
fluid, including without limitation a VITROS slide. For avoidance of doubt, the
term “Dry Slide” shall not include any assay based on immunomagnetic particle
technology or any assay for which the analyte is DNA or RNA.       “Effective
Rebate Rate”   For any year, the weighted average percentage reduction in the
purchase price of any slides purchased in such year that IDEXX is entitled to
receive pursuant to Section 7.03 hereunder. The calculation of the Effective
Rebate Rate is illustrated in Schedule 7.       “Exclusivity Territory”  
Austria, Belgium, France, Germany, Italy, Netherlands, Portugal, Spain,
Switzerland and the United Kingdom.       “Existing Special [**] Slides”  
VETTEST slides that have been [**], as of the date of this Agreement, pursuant
to Section 4 of the Operations Agreement.       “IDEXX Parent”   IDEXX
Laboratories, Inc., a Delaware, USA corporation, the parent company of IDEXX.  
    “IDEXX US”   IDEXX Operations, Inc., a Delaware, USA corporation.       “New
Analyzer”   A new chemistry analyzer that uses OCD Dry Slides for veterinary
applications, as contemplated by

2

--------------------------------------------------------------------------------

 

          Article 3 of the US Agreement, and any updates or modifications to
such analyzer.       “New Chemistry Slides”   As defined in Section 5.06.      
“New Slide/Panel Design”   A new slide format for VETTEST slides to be used in
conjunction with the New Analyzer, as well as a panel holder for such slides, as
contemplated by Article 3 of the US Agreement, and any updates or modifications
to such design.       “New Slides”   VETTEST slides that are formatted and
packaged in accordance with the New Slide/Panel Design, as contemplated by
Article 3 of the US Agreement.       “New Special [**] Slides”   VETTEST slides
that have been [**] pursuant to Section 7.04 of this Agreement.      
“Operations Agreement”   The Operations Agreement effective as of January 1,
1999 among OCD, IDEXX Parent and IDEXX.       “PANELS/PROFILES”   Packages of
VETTEST slides for VETTEST Analyzers consisting of two or more sets of slides of
specified chemistries. The initial PANEL and the initial PROFILES shall consist
of the slides set forth on Schedule 3 attached hereto, with any changes or
additional PANELS/PROFILES to be mutually agreed upon by the parties as
specified in Schedule 3.       “Prime Rate”   For any day in any calendar month,
the prime rate of interest as published in the Wall Street Journal on the last
business day of the immediately preceding month.       “Proportionate Share”  
The percentage obtained by dividing (i) the number of VETTEST slides purchased
by IDEXX in a given period, by (ii) the total number of VETTEST slides purchased
by IDEXX and its affiliates during such period.       “Settlement Agreement”  
The Amendment, Release and Settlement Agreement dated as of September 12, 2002
among OCD, IDEXX Parent and IDEXX.

3

--------------------------------------------------------------------------------

 

      “Special [**] Slides”   Existing Special [**] Slides and New Special [**]
Slides.       “Term”    As defined in Section 18.01.       “Territory”   The
European Union, Africa, and the countries listed on Schedule 10 attached hereto.
      “VETTEST Analyzer”   The analyzer currently marketed as the VETTEST VT
8008 analyzer and any updates or modifications to such analyzer.       “VETTEST
slides”   Dry Slides currently manufactured by OCD, specially designed, bar
coded, labeled, and/or packaged for one or more of the Analyzers in accordance
with the terms of this Agreement or the US Agreement and supplied by OCD in
accordance with the terms and conditions of this Agreement.       “VETTEST tips”
  Metering tips sourced by OCD for use with the VETTEST Analyzer, specially
packaged and supplied to IDEXX in accordance with the terms of this Agreement.  
    “VITROS slides”   The Dry Slides currently manufactured by OCD for use in
any current VITROS analyzer, including without limitation the DT60.

All references to currency in this Agreement shall mean U.S. Dollars unless
otherwise specifically indicated.

2.   EFFECTIVE DATE OF AGREEMENT

      2.01   This Agreement shall become effective upon the Commencement Date.
This Agreement shall apply solely within the Territory.

3.   NEW SLIDES AND THE NEW SLIDE/PANEL DESIGN

      3.01   Notwithstanding any other provision of this Agreement, OCD’s
obligations hereunder to supply, format or package New Slides hereunder shall be
conditioned upon the successful development of the New Slides, the New Analyzer
and the New Slide/Panel Design in accordance with Article 3 of the US Agreement.

4

--------------------------------------------------------------------------------

 

  3.02   If IDEXX US elects under Section 3.08 of the US Agreement to perform
the formatting and packaging of the New Slides independently of OCD, then (1) in
lieu of New Slides, OCD shall supply IDEXX with VITROS slides in the format
currently manufactured for the VITROS mainframe analyzers and/or the VETTEST
Analyzer (i.e., VITROS slides packaged in 50-count cartridges, before further
formatting and packaging for VETTEST Analyzer requirements), as applicable for
New Slides, for the Term as provided in this Agreement, and all references in
this Agreement to New Slides or to VETTEST slides, to the extent referring to
OCD’s obligation to supply New Slides, shall mean such VITROS slides packaged in
50-count cartridges and (2) solely with respect to New Slides, the prices for
Tiers 2 and 3 in the table set forth in Section 7.02 shall be reduced by $[**]
per New Slide.

4.   AGREEMENT TO SUPPLY

  4.01   Subject to the terms and conditions of this Agreement, OCD undertakes
to manufacture for IDEXX and to supply to IDEXX VETTEST slides, VETTEST tips and
Vetrol controls. OCD shall supply VETTEST slides in compliance with the VETTEST
Slide Quality Assurance Procedures set out in Schedule 1. All slides supplied to
IDEXX hereunder are supplied solely for sale within the Territory; provided that
IDEXX may make limited sales to IDEXX US solely for purposes of adjusting
inventory levels according to unanticipated changes in regional demand. For the
avoidance of doubt, nothing in this Agreement shall obligate OCD, with respect
to any particular chemistry, to furnish IDEXX with slides for such chemistry in
any slit format that OCD does not currently manufacture for such chemistry, or
that would otherwise be uneconomical for OCD to supply to IDEXX (other than the
slit formats for such chemistry that OCD then sells or has agreed in writing to
sell to IDEXX).     4.02   (a) Notwithstanding any other provision of this
Agreement, if after [**] the annual volume of VETTEST slides purchased by IDEXX
and IDEXX US is less than [**] slides, then OCD may in its sole discretion elect
to be released from any obligation to format and package the New Slides and/or
package other VETTEST slides, in which event IDEXX’s sole options hereunder
shall be either (x) to accept an increase in slide prices for New Slides and/or
other VETTEST slides that is adequate to compensate OCD for any increase in its
costs due to such reduction in volume, or (y) with respect to slides for which
IDEXX does not accept a price increase under the preceding clause (x), but which
IDEXX US has elected to format and/or package independently of OCD as provided
in Section 4.02 of the US Agreement, to obtain such slides from IDEXX US.

      (b) If IDEXX US elects under Section 4.02 of the US Agreement to perform
the formatting and packaging of New Slides, then (1) in lieu of New Slides OCD
shall supply IDEXX with VITROS slides in the format currently manufactured for
the VITROS mainframe analyzers and/or the VETTEST Analyzer (i.e., VITROS

5

--------------------------------------------------------------------------------

 

      slides packaged in 50-count cartridges, before further formatting and
packaging for VETTEST Analyzer requirements), as applicable for New Slides, for
the Term as provided in this Agreement, and all references in this Agreement to
New Slides or to VETTEST slides, to the extent referring to OCD’s obligation to
supply New Slides, shall mean such VITROS slides packaged in 50-count
cartridges, and (2) the prices for Tiers 2 and 3 in the table set forth in
Section 7.02 shall be reduced by $[**] per New Slide.         (c) If IDEXX US
elects under Section 4.02 of the US Agreement to perform the packaging of
VETTEST slides other than New Slides, then (1) in lieu of such other VETTEST
slides OCD shall supply IDEXX with VITROS slides in the format currently
manufactured for the VETTEST Analyzer (i.e., VITROS slides packaged in 50-count
cartridges, before further formatting and packaging for VETTEST Analyzer
requirements) for the Term as provided in this Agreement, and all references in
this Agreement to VETTEST slides, to the extent referring to OCD’s obligation to
supply such slides (other than New Slides), shall mean such VITROS slides
packaged in 50-count cartridges, and (2) the prices for Tiers 1, 2 and 3 in the
table set forth in Section 7.02 shall be reduced by $[**]per slide for VETTEST
slides (other than New Slides).

5.   FORECASTS, COMMITMENTS AND ORDERS

  5.01   Attached hereto as Schedule 4 are aggregate Purchase Commitments by
IDEXX and IDEXX US for VETTEST slides for the VETTEST Analyzer for calendar
years 2003 through and including 2010. The Purchase Commitments constitute the
aggregate anticipated minimum aggregate purchase quantities by IDEXX and IDEXX
US for single chemistry VETTEST slides and PANELS/PROFILES slides in the
indicated calendar years.         Existing Special [**] Slides, New Special [**]
Slides and New Chemistry Slides shall be excluded from the determination of
IDEXX’s and IDEXX US’s slide purchases for purposes of achieving their aggregate
Purchase Commitments under Section 5.01 of this Agreement or the US Agreement,
as the case may be.         Failure by IDEXX and IDEXX US to purchase, in the
aggregate, at least the indicated Purchase Commitment quantities of each type of
slides in any year may subject IDEXX to the requirement to make a payment to OCD
as set forth in Section 5.02 below, but such failure shall in no event otherwise
be deemed to be a breach of this Agreement.               5.02   If IDEXX and
IDEXX US fail to purchase in the aggregate the quantities of slides for the
VETTEST Analyzer set forth as Purchase Commitments on Schedule 4 in a particular
calendar year, unless there has been a Material Adverse Change (as defined in
the following paragraph), IDEXX shall pay, or shall cause IDEXX US to pay, to
OCD within 30 days after the end of such calendar year [**]% of the

6

--------------------------------------------------------------------------------

 

      product of (i) the number of each type of slides (single or
PANELS/PROFILES) by which IDEXX and IDEXX US have in the aggregate fallen short
of the Purchase Commitment and (ii) the lowest per-slide price for the
applicable type of slides under either of the Agreements.         For the
purposes of this Section 5.02, “Material Adverse Changes” shall mean material
changes in the veterinary clinical chemistry markets which result from (a) the
commercial introduction into the veterinary market, other than by IDEXX or its
affiliates, of a technology not previously available in the veterinary clinical
chemistry market, (b) the eradication of one or more diseases, or the
development of new disease therapies, treatments or diagnostics, which
significantly reduces demand for veterinary clinical chemistry testing or
(c) the inability or unwillingness of OCD to supply VETTEST or VITROS slides in
accordance with IDEXX’s Annual Purchase Forecasts pursuant to Section 5.04
below. Whether a Material Adverse Change has occurred will be determined by
reference to the effect of a change in the veterinary clinical chemistry market
on IDEXX and IDEXX US taken as a whole, and not on either individually.        
The parties shall discuss in good faith any assertion by IDEXX or IDEXX US that
a Material Adverse Change has occurred or is continuing. If the parties agree
that a Material Adverse Change has occurred or is continuing, they shall
negotiate in good faith with respect to appropriate reductions in Purchase
Commitments, VETTEST slide prices (including single and PANELS/PROFILES slides)
and/or amounts which would otherwise be payable pursuant to the first sentence
of this Section 5.02 to appropriately allocate the effects of such Material
Adverse Change on the parties.     5.03   Order and delivery of VETTEST slides
(including PANELS/PROFILES) shall be made in multiples of 100 boxes. Unless
otherwise agreed between the parties in any particular case, IDEXX shall place
orders for slides four times per calendar year, for delivery in each calendar
quarter of the year. Each order shall specify a business day delivery date for
each delivery, which shall be not less than three months after the order date.
Unless otherwise agreed between the parties in any particular case the number of
deliveries shall be limited to four per year. IDEXX shall order quantities for
delivery in any quarter in accordance with its good faith estimates of actual
demand, with allowance for reasonable inventory management requirements and
consistent with IDEXX’s stated desire to minimize its inventory levels.        
Order and delivery of the VETTEST tips shall be made in multiples of 10,000 tips
(20 cartons each containing 500 tips). Unless otherwise agreed between the
parties in any particular case, the number of orders and deliveries of the
VETTEST tips and Vetrols shall be limited to two in each year. OCD shall deliver
the VETTEST tips and Vetrols in the ordered quantities in each year.

7

--------------------------------------------------------------------------------

 

  5.04   Not later than October 1 of each year, commencing October 1, 2003,
IDEXX shall notify OCD of the aggregate forecasted requirements of IDEXX for the
subsequent calendar year for each of the VETTEST slides (single slides and
PANELS/PROFILES slides for the VETTEST Analyzer and New Slides) (each such
notification, an “Annual Purchase Forecast”). The aggregate order quantities in
the subsequent year for each of the VETTEST slides shall be within ±25% of such
aggregate Annual Purchase Forecast unless the parties otherwise agree. As long
as slide orders do not exceed the applicable Annual Purchase Forecast by more
than 25%, OCD shall deliver the slides in accordance with the orders. The Annual
Purchase Forecasts constitute non-binding forecasts for OCD’s planning purposes
and shall also be the basis for determining estimated slide pricing pursuant to
Section 7.02 below and the cash rebate pursuant to Section 7.03 below.        
In addition to the Annual Purchase Forecast, IDEXX shall furnish to OCD updated
quarterly forecasts of the aggregate requirements of IDEXX for VETTEST slides in
the four succeeding calendar quarters. The parties understand that such
forecasts are merely estimates to assist OCD in production planning and are not
to be considered orders or binding in any way.         For production planning
purposes, the parties shall further coordinate with one another to keep OCD
apprised of IDEXX’s current and anticipated inventories of stock keeping units
and relevant conditions in the veterinary market. The provisions of this
paragraph shall terminate immediately upon any termination of the corresponding
provisions of Section 5.04 of the US Agreement.     5.05   In the event that
IDEXX in any year notifies OCD that it wishes to order quantities which exceed
the quantities mentioned in Section 5.04 above by more than 25%, OCD will
endeavor to supply the excess quantities and notify IDEXX of the extent of its
ability to so supply.     5.06   It is understood and agreed that orders for the
VETTEST slides shall include only those chemistries set forth in Schedule 5
hereto, as amended from time to time by agreement of the parties. IDEXX may at
any time request that the additional chemistries listed on Schedule 8 hereof, in
the form they are available at the Commencement Date to the human market on
VITROS slides, be added as VETTEST slides to Schedule 5 (any VETTEST slides so
added, containing such additional chemistries, are referred to herein as “New
Chemistry Slides”). Prior to adding a New Chemistry Slide on Schedule 5, the
parties will negotiate in good faith to determine the initial price for such
slides in accordance with the immediately following paragraph and shall set
forth such price on Schedule 6. IDEXX shall have the right, from time to time,
to elect to remove any New Chemistry Slides from Schedule 5, and Schedule 5 and
Schedule 6 shall be updated to reflect such removal. IDEXX acknowledges that
neither this nor any other provision of this Agreement shall obligate OCD to
supply IDEXX with any

8

--------------------------------------------------------------------------------

 

      slide or other product based on any technology that is not incorporated in
the VITROS slides or VETTEST slides that OCD sells as of the date hereof.      
  Until [**], the price per slide for any New Chemistry Slides shall be the
greater of $[**] and [**] (as determined by OCD in good faith and taking into
account IDEXX’s and IDEXX US’s good faith forecast for the quantity of the
chemistry in question). For orders placed for delivery during each calendar year
beginning with [**], if [**] of any New Chemistry Slide is determined to be
greater than $[**] (as determined by OCD in good faith and taking into account
IDEXX’s and IDEXX US’s good faith forecast for the quantity of the chemistry in
question), then the minimum price per slide for such New Chemistry Slides shall
be [**]; provided, that so long as IDEXX and IDEXX US order [**] or more of such
slides in the aggregate in any calendar year, the minimum price per slide for
such New Chemistry Slides shall not exceed $[**]. OCD shall have the right, from
time to time and in good faith, to revise its determination of [**] of any New
Chemistry Slide that is priced on Schedule 6 if IDEXX’s and IDEXX US’s aggregate
actual annual orders of such slide fall below [**], and Schedule 6 shall be
updated to reflect such revised [**].         In the event that a chemistry
listed in Schedule 5 should become known by OCD to be unavailable at any future
date during the Term, OCD will so notify IDEXX at the earliest practicable date,
and the parties shall cooperate to determine an appropriate course of action.

6.   DELIVERY

  6.01   Following acknowledgement by OCD of each order placed by IDEXX and on
or before the delivery due date, OCD shall complete delivery of the appropriate
quantity of slides and tips within ± 10%. Deviations of delivery quantities from
order quantities within the ± 10% range may be compensated by IDEXX in the first
subsequent order placed, subject to Section 5. In the event of a price increase
for one or more of the VETTEST slides, such compensating quantity of such slides
shall be processed at the previous lower price.     6.02   Order and delivery
for all purchases hereunder shall be F.O.B. OCD’s facility in the U.S.A.    
6.03   Unless otherwise advised in writing by OCD to IDEXX, OCD shall pack the
VETTEST slides in accordance with OCD’s standard shipping configuration which is
known to IDEXX and which at the Commencement Date contains approximately 60
cases per pallet, each case containing 100 boxes of slides.     6.04   The
parties shall reasonably cooperate to identify and implement potential savings
for both parties, consistent with the principles of lean manufacturing across
the value chain, in all processes in their relationship, including without
limitation

9

--------------------------------------------------------------------------------

 

      improvements relating to slide manufacturing, packaging, ordering, build
schedules, component purchasing, delivery schedules, quality testing and
calibration processes, and product distribution processes (including direct
shipment to IDEXX distributors and end-users), and including without limitation,
identifying and implementing processes to reduce the number of slide lots
supplied to IDEXX and to reduce IDEXX calibration time; provided, that neither
party shall be obligated to implement a process change for which its net costs
exceed its net benefits.

7.   PRICES

  7.01   Subject to the provisions of Sections 3.02 and 4.02 that contemplate
OCD’s delivery of slides in 50-count cartridges if IDEXX US elects to format
and/or package slides independently, all references to pricing for VETTEST
slides in this agreement refer to the completed and packaged product in form
ready for delivery to an end-user. The initial prices for each of the VETTEST
slides (including the PANELS/ PROFILES) shall be as set forth in Schedule 5
hereto.     7.02   (a) The prices set forth in Schedule 5 shall remain in effect
for orders placed through December 31, [**].         (b) For orders placed for
delivery during each calendar year beginning with [**], the price for each
VETTEST slide listed on Schedule 5 (whether New Slides, single chemistry VETTEST
slides for the VETTEST Analyzer, or per slide in PANELS/PROFILES, and, for
avoidance of doubt, including New Chemistry Slides, subject to Section 5.06),
within the respective volume tiers set forth below (aggregating for this purpose
purchases by IDEXX and IDEXX US) shall be as set forth for such volume tier;
provided, that Existing Special [**] Slides and New Special [**] Slides shall
not be priced by reference to the volume tiers but will be priced as otherwise
set forth below. For purposes of determining purchase volumes, up to [**]
Existing Special [**] Slides shall be included in the determination, and all
other Existing Special [**] Slides and New Special [**] Slides shall be excluded
from the determination. The stated price shall apply only to slides purchased
within the corresponding volume tier, and only with respect to the quantities
within such tier.

          Annual Volume Tier   Price per Slide

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

Tier 1: Up to [**]
  $ [**]  
Tier 2: In excess of [**] but not exceeding [**]
  $ [**]  
Tier 3: In excess of [**]
  $ [**]  

10

--------------------------------------------------------------------------------

 

      For all orders for Existing Special [**] Slides, the price per slide shall
be as agreed between the parties pursuant to Section 4 of the Operations
Agreement.         For all orders for New Special [**] Slides, the price per
slide shall be as agreed between the parties pursuant to Section 7.04 of this
Agreement.         Notwithstanding the foregoing, the price per slide for any
New Chemistry Slide that is priced on Schedule 6 shall never be lower than the
greater of (a) the minimum price as determined in accordance with Section 5.06
and identified on Schedule 6 as amended from time to time and (b) the price that
would otherwise apply pursuant to the pricing tiers set forth above.        
Promptly after IDEXX and IDEXX US provide their aggregate Annual Purchase
Forecast for a calendar year pursuant to Section 5.04 and Section 5.04 of the US
Agreement, the parties shall calculate the weighted average price of slides
included in such forecast (the “First Estimated Blended Price”).         Upon
determination of the First Estimated Blended Price applicable to a calendar
year, for each order placed by IDEXX for delivery during the first three
calendar quarters of such year, the amount invoiced and paid per slide listed on
Schedule 5 shall be the First Estimated Blended Price.         Before IDEXX
places its order for the fourth calendar quarter of the year, the parties shall
review IDEXX’s and IDEXX US’s respective fourth-quarter orders and re-calculate
the weighted average price of slides based on IDEXX’s and IDEXX US’s aggregate
actual orders for the first three quarters and their orders for the fourth
quarter (the “Second Estimated Blended Price”). If the Second Estimated Blended
Price is different than the First Estimated Blended Price, the amount invoiced
and paid per slide listed on Schedule 5 shall be the Second Estimated Blended
Price. In addition, either party may calculate the resulting adjustment (up or
down) for each slide delivered for the first three quarters to reflect the
difference between the First Estimated Blended Price and the Second Estimated
Blended Price, such that the amount paid by IDEXX for all slides delivered
during the first three calendar quarters shall equal the Second Estimated
Blended Price. If the adjustment is an upwards adjustment, then IDEXX shall pay
OCD the aggregate amount of such adjustment, together with interest on such
amount (calculated as set forth below), within 30 days of OCD’s request for such
payment. If the adjustment is a downwards adjustment, then OCD shall pay IDEXX
the aggregate amount of such adjustment, together with interest on such amount
(calculated as set forth below), within 30 days of IDEXX’s request for such
payment (or, at IDEXX’s option, apply such amount as a credit against IDEXX’s
third or fourth quarter invoice).         Within 30 days after the end of the
year (or 30 days after IDEXX and IDEXX US complete payment in full for all
slides purchased during the year, if later), the

11

--------------------------------------------------------------------------------

 

      parties shall perform a final calculation of the weighted average price
based on all slides ordered by IDEXX and IDEXX US and delivered during the year
(the “Final Blended Price”). If the Final Blended Price is different than the
Second Estimated Blended Price, then IDEXX or OCD, as the case may be, shall
make a final payment to the other, so that the final amount paid by IDEXX per
slide for all slides ordered and delivered during the year shall equal the Final
Blended Price. The party obligated to make such final payment shall do so within
30 days after the determination of the Final Blended Price.         Any
adjustment payments made pursuant to either of the immediately preceding
paragraphs, and any overdue payments by OCD or IDEXX of any amounts owed to the
other pursuant to this Section 7.02, shall bear interest at a rate per annum
equal to the Prime Rate. Such interest shall be calculated based on a 365-day
year and the actual number of days elapsed since the due date for the applicable
payment to which it relates.         For avoidance of doubt, the blended price
calculations of this Section 7.02 shall apply only to chemistries listed on
Schedule 5, and only after calendar year [**].         (c) OCD may, at its
option, increase all prices for slides ordered for delivery (i) on or after
January 1, [**] by an amount not to exceed [**]% of the “PPI Increase” (as
defined below), provided that OCD may not increase prices under this clause
(i) unless the PPI Increase is greater than [**]%; and (ii) on or after
January 1, [**] by an amount (x) as provided in the preceding clause (i) or
(y) by an amount not to exceed [**]% of the PPI Increase, provided that OCD may
not increase prices under this subclause (y) unless the PPI Increase is greater
than [**]%. OCD may calculate the PPI Increase each year beginning in [**], and
any resulting price increase shall be effective for orders placed for delivery
during the following calendar year and thereafter, unless and until increased
again in accordance with the procedures set forth in this paragraph. For
purposes of this Agreement, the “PPI Increase” shall be calculated by dividing
(x) the average monthly “PPI” level for the most recent 12-month period ending
with and including June of the year in which the PPI Increase is being
calculated (each such period, a “Measurement Period”), by (y) the average
monthly PPI level for the 12-month period immediately preceding that described
in clause (x) (the “Baseline Period” with respect to such Measurement Period),
then subtracting 1 and converting the remaining fraction into a percentage. All
calculations shall be based on the latest version of the PPI level published as
of the date the calculation is made. For purposes of this Agreement, “PPI” means
the United States Producer Price Index – [**] (not seasonally adjusted), current
series identification [**], as published by the Bureau of Labor Statistics on
its Web site (www.bls.gov/ppi), or if not available from such Web site, then as
published by the Bureau of Labor Statistics in its monthly periodical “Producer
Price Indexes.” OCD shall give IDEXX written notice of any price increase
pursuant to this paragraph 7.02(c) at least 120 days before the beginning of the
calendar year for which a price increase

12

--------------------------------------------------------------------------------

 

      is to take effect; otherwise, the prices shall remain unaffected by such
increase for such year.         (d) With respect to slides ordered for delivery
on or after January 1, [**], if OCD’s aggregate cost of [**] (as defined below)
for the most recent Measurement Period has increased on a per VETTEST slide
basis as compared with the applicable Baseline Period by an amount that exceeds
the PPI Increase for such Measurement Period as applied to the [**] for such
Baseline Period, on a per VETTEST slide basis, then OCD shall be permitted to
increase the price of each slide sold to IDEXX by the amount of such excess.
“[**]” means [**] that are [**]. Schedule 9 attached hereto contains an example,
for illustration purposes only, of the calculations described in this paragraph
7.02(d) and in paragraph 7.02(e).         (e) With respect to slides ordered for
delivery on or after January 1, [**], if IDEXX’s share of Special Event Costs
(as defined below) for the most recent Measurement Period has increased on a per
VETTEST slide basis as compared with the applicable Baseline Period by an amount
that exceeds [**] above the PPI Increase for such Measurement Period as applied
to IDEXX’s share of Special Event Costs for such Baseline Period, on a per
VETTEST slide basis, then OCD shall be permitted to increase the price of each
slide sold to IDEXX by the amount of such excess. “Special Event Costs” means
the aggregate net amount of (i) [**] with respect to [**] on which [**], (ii)
[**] in the [**], and (iii) [**] as a result of [**]. “IDEXX’s share” of any of
the foregoing shall mean the [**] that is attributable to the [**].        
(f) OCD shall give IDEXX written notice of any price increase pursuant to
paragraph 7.02(d) or 7.02(e) at least 120 days before the beginning of the
calendar year for which a price increase is to take effect; otherwise, the
prices shall remain unaffected by such increase for such year. Any price
increase pursuant to paragraph 7.02(d) or 7.02(e) shall be effective for orders
placed for delivery during the following calendar year and thereafter, unless
and until (i) increased again in accordance with the procedures set forth in
such paragraphs or (ii) there occurs a decrease in any of the costs upon which
the price increase was based (or any such cost that was relevant in one
measuring period is not relevant in subsequent periods, for example, certain
validation or other one-time costs incurred for compliance purposes), in which
event IDEXX’s price per slide shall be reduced to the extent of such decrease
(or one-time cost). In addition, OCD agrees to consider in good faith any
request by IDEXX to reimburse OCD pursuant to paragraph 7.02(e) by a process
other than an increase in slide prices, such as a lump sum payment or series of
payments. Furthermore, with respect to any one-time cost or other temporary cost
lasting no more than one year, IDEXX shall have the right to make such
reimbursement in equal periodic payments (no less frequently than quarterly)
over a period that is no longer than one year.

13

--------------------------------------------------------------------------------

 

      (g) OCD shall give IDEXX reasonable detail as to its incremental [**]
costs and incremental Special Event Costs on which it seeks to base a price
increase pursuant to paragraph 7.02(d) or 7.02(e) or otherwise pass on to IDEXX
pursuant to paragraph 7.02(f); provided, however, that IDEXX shall not have any
right to obtain any details concerning OCD’s actual costs (other than such
incremental cost differences used in such calculation).         (h) At any time
after OCD’s aggregate annual sales volume of VITROS slides and VETTEST slides
shall have declined more than [**]% from [**], the parties shall, at OCD’s
request, discuss appropriate pricing of slides under this Agreement. Neither
party shall be obligated to agree to any price change under this
Section 7.02(h).         (i) OCD agrees that IDEXX shall have the right, no more
than once per calendar year, to cause an internationally recognized independent
accounting firm to conduct an audit, on reasonable advance notice and during
normal business hours, of OCD’s books and records to the extent reasonably
necessary to confirm OCD’s price increase calculations under this Section 7.02.
Any report prepared by such independent accounting firm shall contain such
firm’s conclusion concerning the validity of OCD’s price increase; provided,
however, that such report shall not contain, and IDEXX shall not have any right
to obtain, any details concerning OCD’s actual costs (other than incremental
cost differences used in the calculation of OCD price increases).        
(j) IDEXX agrees that OCD may audit IDEXX’s books and records relating to orders
of VETTEST slides to confirm the pricing calculations under this Section 7.02.

  7.03   The provisions of this Section 7.03 shall apply only to purchases of
VETTEST slides for the VETTEST Analyzer during calendar years [**]. IDEXX shall
be entitled to receive its Proportionate Share (based on sales during a calendar
year) of a cash rebate in the amount set forth below if the total aggregate
slide purchases by IDEXX and IDEXX US, in calendar year [**], exceed the
aggregate quantities set forth below:

          Incremental Cash Rebate – Annual Slide Purchases   % Off Purchase
Price 0 [**]   [**]% [**]   [**]% [**]   [**]% [**]   [**]% [**]   [**]% [**]  
[**]% [**] and above   [**]%

14

--------------------------------------------------------------------------------

 

      The rebate amounts set forth above constitute a percentage reduction in
the purchase price of any slides (including both single slides and
PANELS/PROFILES slides) purchased above the corresponding quantity. The
percentage amounts are incremental (as opposed to cumulative) and relate only to
the quantities set forth opposite it. For example, if IDEXX and IDEXX US were to
purchase, in the aggregate, [**] slides in calendar year [**], they would not be
entitled to a [**]% price reduction on all slides that they purchased in such
year, rather, they would be entitled to receive (i) [**] purchase price
reduction on the first [**] slides purchased, (ii) a [**]% purchase price
reduction on all slides purchased over [**], up to and including [**], (iii) an
[**]% purchase price reduction on all slides purchased over [**] up to and
including [**], and (iv) a [**]% purchase price reduction on all slides
purchased over [**] up to and including the [**] slides that they purchased. The
foregoing notwithstanding, it is understood and agreed that if IDEXX and IDEXX
US do not, in the aggregate, achieve the aggregate Purchase Commitments set
forth in Section 5 in any calendar year, then they shall not be entitled to
receive a rebate for such year.         In the beginning of calendar year [**],
OCD shall calculate an estimated Effective Rebate Rate (the “Estimated Rebate
Rate”) based on the lesser of (i) IDEXX’s and IDEXX US’s aggregate Annual
Purchase Forecast for such year and (ii) [**]% of the total aggregate number of
slides that IDEXX and IDEXX US together purchased in [**]. The Estimated Rebate
Rate for calendar year [**]shall be such that the average VETTEST slide price
for [**], after giving effect to the rebate, shall be $[**]. Not later than
thirty (30) days after the end of each of the first three calendar quarters of
[**] (or thirty days after IDEXX and IDEXX US complete payment in full for
slides purchased during such quarter, if later), OCD shall pay to IDEXX its
Proportionate Share (based on purchases during the preceding quarter) of an
amount equal to the aggregate estimated rebate payment that IDEXX and IDEXX US
would together be entitled to receive in such quarter (the “Estimated Rebate
Payment”). The Estimated Rebate Payment for any such quarter shall be calculated
by (i) multiplying the Estimated Rebate Rate in effect during such quarter by
the total aggregate purchase price for the VETTEST slides purchased by IDEXX and
IDEXX US during such quarter and (ii) subtracting from such amount an amount
equal to [**]% of the total calculated in clause (i) above. The foregoing
notwithstanding, if, in calendar year [**], (i) IDEXX’s and IDEXX US’s total
aggregate slide orders for the immediately preceding calendar year were less
than [**]% of their aggregate Annual Purchase Forecast for such preceding
calendar year or (ii) OCD determines, in its reasonable discretion, at any time
after the end of the second calendar quarter of such calendar year, or IDEXX
indicates at any time, that IDEXX and IDEXX US are reasonably unlikely to meet
their aggregate Annual Purchase Forecast for such year, then OCD shall have the
right to recalculate the Estimated Rebate Rate based on IDEXX’s and IDEXX US’s
aggregate Purchase Commitment for such year (such recalculated rate being
hereinafter referred to as the “New Estimated Rebate Rate”). If OCD elects to
recalculate the Estimated Rebate Rate pursuant to the immediately

15

--------------------------------------------------------------------------------

 

      preceding sentence, (i) OCD shall notify IDEXX in writing which notice
shall set forth the New Estimated Rebate Rate, (ii) OCD shall calculate all
remaining quarterly Estimated Rebate Payments (which may include the Estimated
Rebate Payment for the second calendar quarter) using the New Estimated Rebate
Rate and (iii) all such Estimated Rebate Payments shall be made in accordance
with this sub-clause 7.03, except that such Estimated Rebate Payments shall be
less the amount by which the aggregate Estimated Rebate Payments received by
IDEXX and IDEXX US during the then current calendar year exceed the aggregate
Estimated Rebate Payments they would have received during such calendar year if
the New Estimated Rebate Rate were in effect from the first day of such calendar
year.         Notwithstanding any provision in this Agreement to the contrary,
OCD shall not be required to pay to IDEXX its Proportionate Share of any
Estimated Rebate Payments in any calendar year if (A) any amounts payable to OCD
from IDEXX pursuant to this Agreement are overdue, unless such amounts are being
disputed in good faith by IDEXX, or (B) OCD determines in its reasonable
judgment that IDEXX and IDEXX US are reasonably unlikely to meet their aggregate
Purchase Commitments for such year. In the case of clause (B) above, OCD shall
have the right to make such determination at any time after the end of the
second calendar quarter of calendar year [**], as the case may be (or such
earlier time as IDEXX or IDEXX US indicates (through an Annual Purchase Forecast
or otherwise) that their aggregate slide purchases are reasonably likely to be
less than their aggregate Purchase Commitment for such year), provided that OCD
has consulted with IDEXX and given IDEXX an opportunity (which opportunity shall
be available for a period of not less than 5 business days nor more than 10
business days) to demonstrate its and IDEXX US’s intent and ability to meet
their aggregate Purchase Commitments for such year. For the avoidance of doubt,
OCD’s obligation to make any Estimated Rebate Payments shall be suspended during
the period referred to in the immediately preceding sentence and the days in
such period shall not be counted when determining the date by which the next
scheduled Estimated Rebate Payment is due and payable. If, after fulfilling the
requirements set forth in this paragraph, OCD makes the determination described
in clause (B) above, OCD (i) shall promptly notify IDEXX in writing of its
determination and (ii) shall thereafter have the right to cease making Estimated
Rebate Payments for the remainder of such calendar year.         Not later than
thirty (30) business days after the end of the last calendar quarter of calendar
year [**], as the case may be (or thirty days after IDEXX and IDEXX US complete
payment in full for slides purchased during such quarter, if later), OCD shall
pay to IDEXX its Proportionate Share (based on purchases during such calendar
year) of the amount by which (i) the Effective Rebate Rate multiplied by the
total aggregate purchase price for VETTEST slides purchased by IDEXX and IDEXX
US during such calendar year exceeds (ii) the total aggregate amount of the
Estimated Rebate Payments made by OCD to IDEXX and IDEXX US during

16

--------------------------------------------------------------------------------

 

      such calendar year. If the amount in clause (ii) above exceeds the amount
in clause (i) above, OCD shall deliver to IDEXX a written notice of such fact (a
“Reimbursement Notice”) and IDEXX shall pay to OCD, within thirty (30) days of
receipt of such notice an amount in cash equal to its Proportionate Share of the
amount of such excess.         Notwithstanding the foregoing, if IDEXX and IDEXX
US do not achieve their aggregate Purchase Commitment in calendar year [**], as
the case may be, then IDEXX shall return all Estimated Rebate Payments received
from OCD for such year no later than thirty (30) days after the end of such
calendar year.         An illustrative representation of the foregoing rebate
calculation methodology is attached hereto as Schedule 7.        
Notwithstanding any other provision of this Section 7.03, if any amounts payable
to OCD from IDEXX pursuant to this Agreement are overdue, other than amounts
that are being disputed in good faith by IDEXX, then OCD shall be entitled to
withhold such overdue amount (plus any accrued interest) from any rebate
payments to which IDEXX may be entitled. Any overdue payments by OCD or IDEXX of
any amounts owed to the other pursuant to this Section 7.03 shall bear interest
at a rate per annum equal to the Prime Rate. Such interest shall be payable at
the same time as the payment to which it relates and shall be calculated daily
on the basis of a year of 365 days and the actual number of days elapsed.      
  OCD shall prepare a remittance advice to accompany each rebate payment (or
Reimbursement Notice), which shall set forth the reporting period for which the
payment is made (or demanded) and a summary sheet which shall detail OCD’s
calculation of the rebate (or reimbursement). If IDEXX disagrees with the rebate
or reimbursement calculation, IDEXX shall promptly notify OCD, and the parties,
together with IDEXX US if appropriate, shall review the calculations together in
good faith to agree on any appropriate corrections or adjustments.         Any
Special [**] Slides and any New Chemistry Slides shall be excluded from the
determination of any rebate entitlement under Section 7.03 of this Agreement or
the US Agreement, as the case may be, and the rebates described in Section 7.03
shall not apply to such slides.     7.04   If IDEXX provides OCD with specific
documentation regarding [**] that would require IDEXX and IDEXX US,
collectively, to purchase, in any calendar year, a number of slides over and
above their most recent aggregate Annual Purchase Forecast for such year, [**]
for slides, [**] for slides [**] by this Agreement, OCD agrees, within two weeks
of its receipt of all additional information that OCD may reasonably request
regarding such [**], to inform IDEXX as to whether or not OCD [**] in respect of
[**], the number of slides [**] for such slides, and any other related terms and
conditions that OCD deems applicable. OCD shall

17

--------------------------------------------------------------------------------

 

      consider such requests in good faith. OCD agrees that [**] IDEXX or IDEXX
US pursuant to [**] remain in effect with respect to [**] until such time as
[**] as the case may be.

8.   INVOICES AND PAYMENT

  8.01   OCD shall invoice IDEXX in respect of each order for the VETTEST slides
upon completion by OCD of the delivery of such order. Each order shall be billed
by OCD under one invoice in US dollars and payment shall be made by IDEXX in US
dollars not later than thirty (30) days following the date of invoice.

9.   EXCLUSIVITY

  9.01   OCD undertakes not to sell or otherwise supply, and to cause its
affiliates not to sell or otherwise supply, any Dry Slides (whether or not such
slides are finished or complete) bar-coded for use in any Analyzers to any
person, firm or company other than IDEXX or its affiliates. The provisions of
this Section 9.01 shall survive the termination of this Agreement unless all of
the following shall be true: (i) prior to such termination IDEXX (or its
permitted assignees) and its affiliates shall have ceased to market the VETTEST
slides, (ii) such cessation shall not have been a consequence of action by OCD,
and (iii) OCD shall have complied with its obligations under this Agreement
prior to such termination.     9.02   IDEXX undertakes not to market, and to
cause its affiliates not to market, any Dry Slide for any chemistry identified
on Schedule 5, as amended from time to time, other than Dry Slides obtained by
such person directly from OCD, to the extent that the desired chemistries are
available from OCD; provided that, for purposes of adjusting inventory levels
according to unanticipated changes in regional demand, IDEXX may purchase from
IDEXX US VETTEST slides that IDEXX US obtained directly from OCD. The provisions
of this Section 9.02 shall terminate [**] years after the Commencement Date with
respect to VETTEST slides for the VETTEST Analyzer, and [**] years after the
first commercial sale of the New Analyzer in the Territory, with respect to New
Slides. At the time of termination (with respect to VETTEST slides for the
VETTEST Analyzer, or New Slides, as the case may be), the parties shall
negotiate whether they wish to renew the arrangements set out in this
Section 9.02 with respect to VETTEST slides for the VETTEST Analyzer, or New
Slides, as the case may be. Any renewal of these arrangements shall be set forth
in a written agreement entered into by the parties.

10.   MARKETING ARRANGEMENTS

  10.01   IDEXX will be responsible for all marketing arrangements for the
Analyzers and the VETTEST slides. IDEXX may appoint any of OCD’s
medical/surgical dealers as distributors of or agents for the Analyzers and the
VETTEST slides but will not be obliged to do so.

18

--------------------------------------------------------------------------------

 

  10.02   IDEXX will be responsible for the establishment of dealer performance
criteria for all dealers including OCD’s medical/surgical dealers (if any are
appointed by IDEXX as distributors of the Analyzers and the VETTEST slides).    
10.03   IDEXX will keep OCD informed of and consult with OCD as to marketing
arrangements for the Analyzers and the VETTEST slides but will not be obligated
to OCD beyond the terms of this Agreement in connection with such marketing
arrangements.     10.04   OCD hereby grants to IDEXX the exclusive right to
distribute, to customers in the veterinary market, under the terms set forth in
this Section 10.04, VITROS slides and VITROS analyzers that run solely VITROS
slides. The parties also agree to use good faith, commercially reasonable
efforts to negotiate a definitive distribution agreement not later than
December 31, 2003. Notwithstanding any other provision of this Section 10.04,
OCD and its affiliates shall continue to have the right to sell, directly or
through distributors, VITROS analyzers and VITROS slides to all persons that are
current VITROS end-user customers as of the Commencement Date, and to renew or
extend the term of any contracts with such customers or, solely for the purpose
of sales to such customers, with such distributors.         The parties shall
discuss terms for any sales opportunity in the veterinary market in good faith,
on a case-by-case basis. OCD shall be responsible, at its sole expense, for
providing warranty and out-of-warranty service and support to any customers to
whom IDEXX sells a VITROS analyzer; provided that such analyzer is then covered
by a maintenance agreement between OCD and that customer. IDEXX shall not modify
or customize any VITROS product supplied hereunder, or remove or alter any
product labels or re-label any products, packaging or related materials for
VITROS product supplied hereunder. OCD shall provide IDEXX, without charge, with
such training in the marketing and sale of VITROS products and with such
marketing and technical assistance and product information as OCD may, in its
discretion, consider necessary to assist with the promotion and sale of the
products; provided that OCD’s training obligation shall be limited to training
employees of IDEXX to train other IDEXX employees and sales agents.        
IDEXX shall defend and indemnify OCD from and against all damages, liabilities,
costs and expenses (including reasonable attorneys’ fees and costs) arising out
of any claim resulting from (a) any negligent act or omission or any willful
misconduct by IDEXX in connection with the VITROS products supplied by OCD under
this Section 10.04 or (b) any statement, representation or warranty made by
IDEXX or any of its agents with respect to a VITROS product that is not
contained in the labeling or package insert and is not otherwise approved by OCD
in writing or (c) any breach of IDEXX’s covenants in the preceding paragraph.
OCD

19

--------------------------------------------------------------------------------

 

      shall defend and indemnify IDEXX from and against all damages,
liabilities, costs and expenses (including reasonable attorneys’ fees and costs)
arising out of any claim (i) for injuries or death to persons or animals or
damage to or destruction of tangible property arising out of the use of VITROS
products sold under this Section 10.04 (whether claimed by reason of breach of
warranty, negligence, product defect or other similar cause of action,
regardless of the form in which any such claim is made) or (ii) that any VITROS
product sold under this Section 10.04 infringes a patent, copyright, trademark
or trade secret of a third party; provided that this clause (ii) shall not apply
to any claim arising out of the use of any product in conjunction with products
not supplied by OCD. The indemnity procedures set forth in Section 16.06 shall
apply to this Section 10.04.         The provisions of this Section 10.04 shall
apply only within the Exclusivity Territory. Furthermore, the provisions of this
Section 10.04 granting IDEXX exclusivity shall (a) automatically terminate
immediately upon the termination of Section 9.02 and (b) not apply to any
instruments weighing more than 200 pounds, or to any slides sold for use on such
instruments, unless and until the parties have executed the distribution
agreement contemplated by this Section 10.04.

11.   SALES SUPPORT

  11.01   IDEXX will be responsible for all necessary sales support for the
Analyzers and the VETTEST slides.     11.02   OCD’s sole obligation in respect
of sale support shall be at its own expense to assist IDEXX in resolving
specific problems resulting from the failure of VETTEST slides to conform to
specifications.

12.   TESTING

  12.01   OCD shall disclose to IDEXX its quality assurance procedures used in
final evaluation of the VETTEST slides and full particulars thereof as set out
in the VETTEST Slide Quality Assurance Procedures forming Schedule 1 to this
Agreement. OCD shall operate such quality assurance procedures in accordance
with Schedule 1.     12.02   Upon prior written notice from IDEXX, OCD shall
grant authorized representatives of IDEXX access to that part of OCD production
facilities which conducts final evaluation of the VETTEST slides for the purpose
of enabling such representatives to monitor the application by OCD of the
VETTEST Slide Quality Assurance Procedures set out in Schedule 1. Such access
shall be granted by OCD to IDEXX and IDEXX US no more than twice in any
twelve-month period. With respect to VETTEST slides for use in the New Analyzer,
IDEXX shall be permitted to monitor those stages of the production process that
are unique to

20

--------------------------------------------------------------------------------

 

      VETTEST slides for the New Analyzer, but with respect to VETTEST slides
for the VETTEST Analyzer, such access shall be limited to OCD’s final evaluation
facilities. All information obtained as a result of the audits contemplated by
this Section 12.02 shall be subject to the provisions of Schedule 2.

13.   BAR CODING AND PACKAGING

  13.01   The VETTEST slides shall be printed by OCD with special bar coding for
use in Analyzers.     13.02   OCD shall package the VETTEST slides and tips for
the VETTEST Analyzer in the physical manner as used for the VITROS slides and
tips at the time of packaging of such VETTEST slides and tips. In the event of a
change in VITROS slide or tip packaging which has an impact on such VETTEST
slide or tip packaging, OCD shall notify IDEXX as early as practicable of the
relevant particulars of such change.     13.03   Except as authorized by
Section 14.01 below, the label content and art work associated with VETTEST
slides and package materials (including without limitation package materials for
the New Slides) shall not include any trademarks, trade names, or trade dress of
OCD. IDEXX shall furnish such label content and art work to OCD on a timely
basis, and such label content and art work shall not be changed at any time
during the Term without the prior agreement of the parties.

14.   TRADE MARKS AND TRADE NAMES

  14.01   OCD expressly authorizes IDEXX to use the phrase “manufactured by
Ortho-Clinical Diagnostics, Inc. for IDEXX (IDEXX ADDRESS)” on package materials
for VETTEST slides (including without limitation package materials for the New
Slides). No other uses of OCD’s trademarks, trade names or trade dress are
authorized by this Agreement.     14.02   IDEXX shall neither acquire, nor claim
any right, title or interest in or to any of OCD’s trade marks or trade names by
virtue of this Agreement or through advertising and sale of the Analyzers or the
VETTEST slides or otherwise.

15.   PATENT INDEMNITIES

  15.01   OCD shall indemnify and hold IDEXX harmless for all loss, damage, cost
and expense whatsoever, including legal fees, patent attorney’s fees and court
costs that IDEXX may incur or become liable for as a result of any action, suit
or claim alleging infringement of any patent held by a third party arising from
the use and/or sale of the VETTEST slides or tips to the extent that such
action, suit, or claim relates in a material way to the specification for the
VITROS slides or tips. If as a result of any judgment or settlement it is
determined that a claim or claims

21

--------------------------------------------------------------------------------

 

      of a third party patent is infringed by the use and/or sale of the VETTEST
slides or tips as aforesaid and IDEXX is required to make any payments to any
third party as a result thereof, IDEXX may off-set all such payments against any
present and/or future payments to be made to OCD hereunder.     15.02   IDEXX
shall indemnify and hold OCD harmless for all loss, damage, cost and expense
whatsoever, including legal fees, patent attorney’s fees and court costs that
OCD may incur or become liable for as a result of any action, suit or claim
alleging infringement of any patent held by a third party arising from (a) the
manufacture, use or sale of the VETTEST slides or tips to the extent that the
VETTEST slides or tips differ from the VITROS slides or tips, (b) the
manufacture, use or sale of the New Slide/Panel Design, or (c) the manufacture,
use or sale of any Analyzer.     15.03   All claims for indemnity under this
Article 15 shall be subject to the rights, obligations and procedures set forth
in Section 16.06 below.

16.   WARRANTY, LIABILITY AND INDEMNIFICATION

  16.01   OCD hereby warrants that:

  (a)   the VETTEST slides delivered to IDEXX shall be in compliance with
Schedule 1, and     (b)   OCD shall pack and ship products under this Agreement
in a manner consistent with OCD’s usual practices, which shall be sufficient to
protect the products from damage during normal shipping and handling.

  16.02   In the event of a breach on the part of OCD of Section 16.01 above,
OCD’s liability shall be limited to the replacement of the VETTEST slides or
tips found to be defective, including shipping costs for return of defective
slides or tips and delivery of replacement slides or tips.     16.03   OCD’s
liability as stated in Section 16.02 shall be subject to the following
conditions:

  (a)   IDEXX shall notify OCD promptly of any noncompliance contrary to
Section 16.01(a) or damage contrary to Section 16.01(b).     (b)   IDEXX and its
transferees shall not alter or modify the VETTEST slides or packaging of the
VETTEST slides or tips without prior approval of OCD.

22

--------------------------------------------------------------------------------

 

  16.04   Except as provided in this Section 16 there are no other warranties,
express or implied, including warranties for fitness for any particular use or
of merchantability.     16.05   Subject to Section 15, IDEXX shall indemnify and
hold harmless OCD from and against any claim, loss, damage, or expense
(including attorney’s fees) with respect to any physical injury to persons,
animals or property arising out of or in connection with IDEXX’s use or sale of
any Analyzer or the VETTEST slides, and any claim of infringement of any
trademark (except OCD’s own trademark), trade dress, trade secret, or copyright.
IDEXX shall notify OCD (a) at the commencement of any action or suit based on
any such claim and (b) in the event of any injunction or other order prohibiting
the sale or use of any Analyzer or VETTEST slide.     16.06   Any party claiming
indemnification under this Agreement (the “Indemnitee”) shall notify the party
from which indemnification is claimed (the “Indemnifying Party”) in writing
promptly upon becoming aware of any claim to which such indemnification may
apply. Failure to provide such notice shall constitute a waiver of the
Indemnifying Party’s indemnity obligations hereunder if, and only to the extent
that, the Indemnifying Party is materially damaged thereby. The Indemnifying
Party shall have the right to assume and control the defense of the claim at its
own expense. If the right to assume and have sole control of the defense is
exercised, the Indemnitee shall have the right to participate in, but not to
control, such defense at its own expense. If the Indemnifying Party does not
assume the defense of the claim, the Indemnitee may defend the claim at the
Indemnifying Party’s expense. The Indemnitee will not settle or compromise the
claim without the prior written consent of the Indemnifying Party. The
Indemnifying Party will not, without the consent of the Indemnitee (which
consent will not be unreasonably withheld), settle or compromise the claim in
any manner which would have an adverse effect on the Indemnitee, unless
(x) prior to such settlement or compromise the Indemnifying Party acknowledges
in writing its obligation to pay in full the amount of the settlement or
compromise and the Indemnitee is furnished with security reasonably satisfactory
to it that the Indemnifying Party can in fact pay such amount, (y) such
settlement or compromise includes a full release of such claim against the
Indemnitee and (z) such settlement or compromise provides for no relief or
remedy other than money damages. The Indemnitee shall reasonably cooperate with
the Indemnifying Party and will make available to the Indemnifying Party all
pertinent information under the control of the Indemnitee.

17.   SECRECY

  17.01   Each of IDEXX, IDEXX Parent and OCD agrees to protect confidential
information disclosed to it upon terms set out in Schedule 2 attached hereto.

23

--------------------------------------------------------------------------------

 

18.   PERIOD OF AGREEMENT

  18.01   Subject to the terms and conditions set forth herein, the term (the
“Term”) of the Agreement shall be the period from the Commencement Date until
December 31, 2018.

19.   TERMINATION

  19.01   This Agreement may be terminated by either party in any of the
following events:

  (a)   If the other party is guilty of gross or persistent breaches of the
terms of this Agreement, which breaches are not remedied to the satisfaction of
the other party after ninety (90) days notice in writing to do so. Any such
breach shall entitle the innocent party to terminate this Agreement by notice in
writing which notice shall be effective at the end of ninety (90) days following
the date of such notice.     (b)   If the other party becomes insolvent or
compounds with its creditors or goes into liquidation (other than for the
purposes of corporate reorganization) then the innocent party may terminate this
Agreement by notice in writing which shall have immediate effect.     (c)   If
such party elects to cease marketing Dry Slide diagnostic products, then it
shall have the right, by notice given at any time after January 1, [**], to
terminate this Agreement upon [**] years’ prior written notice.

  19.02   Changes in the equity ownership or corporate reorganizations of either
party shall not be grounds for termination of this Agreement, except that if
more than [**]% of the outstanding capital stock of IDEXX or IDEXX Parent is
owned or controlled by a competitor of OCD, OCD may in its discretion terminate
the provisions of Section 10.04 of this Agreement immediately upon written
notice to IDEXX.     19.03   This Agreement shall terminate automatically upon
any termination of the US Agreement.     19.04   The provisions of this
Agreement dealing with rights and obligations after termination of this
Agreement, including without limitation Sections 15, 16, 17, 21, 22, 23, 24, 25,
26, 28, 29 and 30, shall survive the expiration or termination of this Agreement
and continue to be enforceable to the extent necessary to achieve the logical
and intended purposes of such provisions.

24

--------------------------------------------------------------------------------

 

20.     FORCE MAJEURE

  20.01   Neither party shall be liable for any failure or delay in performing
any of its respective obligations under this Agreement to the extent that such
failure or delay is due to any cause beyond its reasonable control (a “Force
Majeure Event”). The non-performing party shall give the other party prompt
written notice of such inability to perform and shall use commercially
reasonable efforts to resume performance as soon as reasonably practicable. If
as a result of a Force Majeure Event OCD is unable, using commercially
reasonable efforts, to meet its supply obligations to IDEXX hereunder for a
period exceeding twenty-four months, or if IDEXX reasonably determines that it
will not be feasible for OCD through the use of commercially reasonable efforts
to resume the supply of VETTEST slides within twenty-four months, then either
party may terminate this Agreement immediately upon written notice to the other
party.

21.     GOVERNING LAW; JURISDICTION

  21.01   The construction, validity and performance of this Agreement shall be
governed in all respects by the laws of the State of New York, USA. Any legal
actions relating to this Agreement must be brought in the court of appropriate
jurisdiction in the State of New York, which shall have exclusive jurisdiction,
and the parties hereby waive any claim of lack of jurisdiction or inconvenient
forum. The prevailing party in any litigation under this Agreement shall be
entitled to an award of its costs, including reasonable attorneys’ fees and
expenses. Each party hereto waives its right to trial of any issue by jury. Each
party hereto waives any claim to punitive, exemplary or multiplied damages from
the other. Each party hereto waives any claim of consequential damages from the
other.

22.     SEVERABILITY

  22.01   Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions hereof or the validity
or enforceability of the offending term or provision in any other situation or
in any other jurisdiction. If the final judgment of a court of competent
jurisdiction declares that any term or provision hereof is invalid or
unenforceable, then the parties agree that the court making the determination of
invalidity or unenforceability shall have the power to reduce the scope,
duration, or area of the term or provision, to delete specific words or phrases,
or to replace any invalid or unenforceable term or provision with a term or
provision that is valid and enforceable and that comes closest to expressing the
intention of the invalid or unenforceable term or provision, and this Agreement
shall be enforceable as so modified after the expiration of the time within
which the judgment may be appealed.

25

--------------------------------------------------------------------------------

 

23.   WAIVERS

  23.01   Failure of either party to this Agreement to insist upon strict
observance or compliance with all its terms and conditions in one or more
instances shall not be deemed to be a waiver of its right to insist upon such
observance or compliance with such term or condition or with any other terms or
conditions hereof in the future.

24.   PRIOR AGREEMENTS; INTERPRETATION

  24.01   As of the Commencement Date, this Agreement shall take effect in
substitution for the Prior Europe Agreement, the Operations Agreement (except as
otherwise provided in Section 7.04 of this Agreement), Section B (Amendments) of
the Settlement Agreement, and all or any other previous agreements relating to
the subject matter hereof whether the same are formal agreements or agreements
that would be inferred from the parties’ correspondence or conduct, and all such
substituted agreements shall be deemed to have been terminated by mutual consent
on the Commencement Date; provided, however, that nothing contained herein shall
be deemed to modify or terminate the US Agreement, except that the Purchase
Commitments and Annual Purchase Forecasts referred to in Section 5 and in
Schedule 4 of this Agreement and the US Agreement represent the aggregate
commitments and forecasts of IDEXX and IDEXX US and not the individual
commitments and forecasts of IDEXX US under the US Agreement or IDEXX under this
Agreement. For avoidance of doubt, this Agreement (as it may be amended or
restated from time to time) is the “Europe Agreement” referred to in the US
Agreement.

25.   ENTIRE AGREEMENT

  25.01   This Agreement, together with the US Agreement, the Settlement
Agreement (other than Section B thereof), and that certain memorandum agreement
dated September 12, 2003 regarding slide packaging (as amended to date),
constitutes the complete agreement of the parties concerning the subject matter
hereof and thereof during the Term, and, with respect to all periods from and
after the Commencement Date, supersedes all prior agreements between the parties
regarding its subject matter.

26.   ALTERATION OR MODIFICATION

  26.01   No alteration, amendment or modification to this Agreement or the
attached Schedules shall be of any force or effect unless in writing and signed
by both parties. No modification shall be effected by the acknowledgement or
acceptance of purchase order forms or order confirmations or invoices or other
documents containing different conditions.

26

--------------------------------------------------------------------------------

 

27.   ASSIGNMENT

  27.01   This Agreement shall not be capable of assignment by either party to a
company of which it owns less than a majority or which owns less than a majority
of the party save in the case of (i) an assignment at OCD’s sole discretion to
an acquiror of OCD’s dry slide business or (ii) an assignment at IDEXX’s sole
discretion to an acquiror of IDEXX’s VETTEST and New Analyzer business; provided
that no assignment shall release the assigning party from any obligations
hereunder. In the case of an assignment under the preceding clause (ii) to an
entity which is a competitor of OCD’s diagnostics business, OCD may in its
discretion terminate the provisions of Section 10.04 granting IDEXX exclusivity
or restricting sales or marketing by or on behalf of OCD immediately upon
written notice to IDEXX.         This Agreement shall be binding on and inure to
the benefit of the parties hereto and their permitted successors and assigns.

28.   GOVERNING LANGUAGE

  28.01   This Agreement is drafted in English. If this Agreement is translated
into a language other than English, then the original English version of this
Agreement shall control all questions of interpretation with respect thereto.
Any other documents delivered or given pursuant to this Agreement, including
notices, shall be in English.

29.   NOTICES

  29.01   Any notice, statement or other communication to be given by one party
to the other hereunder may be given by registered mail, airmail, internationally
recognized courier, facsimile or telex to the party concerned at the addresses
set out below:         Ortho-Clinical Diagnostics, Inc.
1001 US Highway 202
Raritan, New Jersey 08869, USA
For the attention of: Vice President and General Manager, Americas         With
a copy to:
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933, USA
For the attention of: Office of General Counsel

27

--------------------------------------------------------------------------------

 

      IDEXX Europe B.V.
Koolhovenlaan 20
1119 NE — Schiphol-Rijk
The Netherlands
For the attention of: Director of European Finance and Administration        
With a copy to:
IDEXX Laboratories, Inc.
One IDEXX Drive
Westbrook, Maine 04092, USA
For the attention of: Office of General Counsel     29.02   Any notice, payment
or communication so given or made shall be deemed to have been received at the
time when in the ordinary course of transmission the same should have reached
its destination. Either party may change its address for the purpose of this
Agreement by giving notice of such change to the other party pursuant to the
provisions of this Section. For purposes of this Section 29, notice given by OCD
to IDEXX US under the US Agreement shall be deemed given to IDEXX.

30.   GUARANTY

  30.01   IDEXX Parent hereby guarantees to OCD the due performance and
observance by IDEXX of all of the provisions of the Agreement to be performed
and observed by it under this Agreement, for which IDEXX Parent shall be jointly
and severally liable, without requiring any notice of non-payment,
non-performance or non-observance, or proof of notice or demand, all of which
IDEXX Parent hereby waives. OCD may proceed against IDEXX Parent separately or
jointly, before, after or simultaneously with proceeding against IDEXX for
default. This guaranty shall not be terminated, affected or impaired in any way
by reason of (i) the assertion by OCD against IDEXX of any of the rights or
remedies reserved to OCD under this Agreement, (ii) the commencement by OCD of
any proceedings against IDEXX, (iii) the granting by OCD of any extensions of
time or indulgence to IDEXX, (iv) any change in or amendment to this Agreement,
or (v) any payment or performance being invalid in connection with any
bankruptcy, insolvency, reorganization or similar proceedings in respect to
IDEXX. This guaranty is absolute and unconditional and shall continue in full
force and effect as to any renewal, extension, amendment, addition, assignment
or transfer or other modification of this Agreement, whether or not IDEXX Parent
shall have been notified of or consented to any such action, and regardless of
bankruptcy or insolvency of IDEXX or the actual or purported rejection by a
trustee in such bankruptcy of this Agreement or any limitation on any claim in
such bankruptcy for damages resulting from the actual or purported termination
of this Agreement

28

--------------------------------------------------------------------------------

 

      or the enforceability in such bankruptcy of this Agreement. IDEXX Parent
hereby agrees that this guaranty shall continue to be effective or shall be
reinstated, as the case may be, if at any time payment of any sum hereby
guaranteed is rescinded or must be otherwise restored or returned by OCD upon
the insolvency, bankruptcy or reorganization of IDEXX, or otherwise, all as
though such payment had not been made.

     IN WITNESS WHEREOF and intending to be legally bound, the parties hereto
have caused this Agreement to be duly executed in duplicate by their respective
authorized representatives the day and year first written above.

              ORTHO-CLINICAL
DIAGNOSTICS, INC.   IDEXX EUROPE B.V.               By:   /s/Tony Zezzo   By:  
/s/Conan R. Deady    

--------------------------------------------------------------------------------

     

--------------------------------------------------------------------------------

    Tony Zezzo,       Conan R. Deady,     Vice President and General Manager,  
    Director     Americas                               Solely as to Sections 17
and 30
IDEXX LABORATORIES, INC.                       By:   /s/Jonathan W. Ayers      
     

--------------------------------------------------------------------------------

            Jonathan W. Ayers,             President and Chief Executive Officer

29

--------------------------------------------------------------------------------

 

Schedule 1 – VetTest® Slide Quality Assurance Procedures

VETTEST Slides for the VETTEST Analyzer:

Introduction

The following procedure constitutes a generic overview of the quality assurance
provisions for finishing of VITROS slides and applies in like manner to product
release for the VETTEST slides.

VETTEST Slide Quality Assurance

VETTEST slides will be produced to the same quality standards as VITROS and DT
60 slides for OCD’s human market unless otherwise agreed to by IDEXX.

Bar Coding

Bar code printing on the VETTEST slides will render the VETTEST slides
incompatible with use in VITROS analyzers. OCD will reserve certain number
sequences for generation of the bar code patterns on the VETTEST slides.

New Slides:

Specifications to be determined by IDEXX US as part of the Development Program
contemplated in the US Agreement and, together with quality assurance
procedures, reasonably agreed in writing by OCD and IDEXX US for purposes of
this Schedule 1.

30

--------------------------------------------------------------------------------

 

Schedule 2

     Section 1. Obligation to Keep Information Confidential. Each party agrees
to hold, and to cause its respective officers, directors, employees,
accountants, counsel, consultants, advisors and agents to hold, in confidence
the terms of the Agreements, and all documents and information concerning the
other party, whether oral or written, furnished or made known to such party in
connection with either of the Agreements or any project or discussion under, or
related to, either of the Agreements; provided that no party shall be required
to keep any information confidential (i) if such party is compelled to disclose
such information by judicial or administrative process or by other requirements
of law (including without limitation the Securities Act of 1933, as amended, and
the Securities Exchange Act of 1934, as amended) and such party has provided
prior written notice to the other party and given such other party reasonable
opportunity to contest disclosure or (ii) to the extent such information can be
shown to have been (A) previously known to such party on a nonconfidential
basis, (B) in the public domain through no fault of such party, (C) later
lawfully acquired from a third party source or (D) independently developed by
such party without reference to confidential information. The foregoing
notwithstanding, any party may disclose information concerning the other party
or the Agreements to its and its affiliates’ officers, directors, employees,
accountants, counsel, consultants, advisors and agents in connection with its
performance of this Agreement so long as such persons are informed by such party
of the confidential nature of such information and are directed by such party to
treat such information confidentially, it being understood and agreed that such
party shall be responsible for any failure to treat such information
confidentially by such persons. The obligation of each party to hold any
information in confidence shall be satisfied if it exercises the same care with
respect to such information as it would to preserve the confidentiality of its
own similar information. The confidentiality provisions of this Schedule 2 shall
remain in effect for so long as this Agreement is in effect and for a period of
three (3) years thereafter.

     Section 2. Public Announcements. No party to this Agreement shall originate
any news release or other public announcement, written or oral, relating to this
Agreement or the US Agreement, without the prior written consent of the other
party, except to the extent such news release or other public announcement is
required by law; provided that in the event an announcement is required by law,
the party issuing same shall still be required to use its commercially
reasonable efforts to consult with the other party or parties named or referred
to in such announcement prior to its release as the circumstances reasonably
permit, in order to allow such other party or parties to comment on the use of
their names or the references to them and, after its release, shall provide such
other party or parties with a copy thereof. If a party has previously reviewed
and approved a public announcement, its further approval shall not be required
with respect to those provisions of subsequent announcements that are
substantially similar in scope and substance to provisions that have been
previously approved. In no event shall IDEXX or IDEXX Parent use the name
“Johnson & Johnson” or “J&J” in any publicity relating to this Agreement or the
US Agreement, whether written or oral, other than to state that OCD is “a
Johnson & Johnson company” or a (wholly-owned) subsidiary of Johnson & Johnson.

31

--------------------------------------------------------------------------------

 

     Section 3. Governing Law. The construction, validity and performance of
this Schedule 2 shall be governed in all respects by the laws of the State of
New York, USA.

     Section 4. Notices. Any notices required to be given under this Schedule 2
shall be given in the manner specified by Section 29 of the Agreement.

32

--------------------------------------------------------------------------------

 

Schedule 3 - Panels/Profiles
(Applicable only to VETTEST Analyzer)

The initial PANEL shall be the “Pre-Anesthetic Panel” consisting of four sets of
the following six VETTEST slides:

      BUN   Urea Nitrogen ALT   Alanine aminotransferase GLU   Glucose TP  
Total protein CREA   Creatinine ALKP   Alkaline phosphatase

[**]The initial PROFILES shall be the “General Health Profile” and the “Large
Animal Profile”, each consisting of two sets of 12 VETTEST slides as follows:

              General Health Profile       Large Animal Profile       ALB  
Albumin   ALB   Albumin ALKP   Alkaline phosphatase   ALKP   Alkaline
phosphatase ALT(SGPT)   Alanine aminotransferase   AST   AST AMYL   Amylase  
Ca2+   Calcium Ca2+   Calcium   CK   CK CHOL   Cholesterol   GGT   Gamma GT CREA
  Creatinine   GLU   Glucose GLU   Glucose   PHOS   Inorganic phosphate PHOS  
Inorganic phosphate   LDH   LDH TBIL   Total bilirubin   MG   Magnesium TP  
Total protein   TP   Total Protein BUN   Urea Nitrogen   BUN   Urea Nitrogen

Packaging for the Pre-Anesthetic Panels, the General Health Profiles and the
Large Animal Profiles for the VETTEST Analyzer has been previously agreed upon
by the parties, and any changes to the slide composition or packaging of the
initial PANEL or the initial PROFILES shall be negotiated in good faith and
mutually agreed upon by OCD and IDEXX. The slide composition, packaging and
initial pricing of any additional PANELS/PROFILES shall be mutually agreed upon
by OCD and IDEXX. Unless otherwise agreed by the parties in writing with respect
to one or more specific PANELS or PROFILES, all purchases by IDEXX or IDEXX US
of VETTEST slides packaged as PANELS/PROFILES shall be credited against the
Annual Purchase Forecasts and Purchase Commitments for such slides under this
Agreement and the US Agreement.

New Slide/Panel Design for the New Analyzer shall be as developed by IDEXX US
under Article 3 of the US Agreement.

33

--------------------------------------------------------------------------------

 

Schedule 4 - Purchase Commitments

          Minimum Slide Purchase Year   Commitment ( [**] )

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

2003   [**] 2004   [**] 2005   [**] 2006   [**] 2007   [**] 2008   [**] 2009  
[**] 2010   [**]

34

--------------------------------------------------------------------------------

 

Schedule 5 - Products and Prices
(as of the Commencement Date)

Customer No.: 314 8251

                  Single Slides (Box of 25)   Catalog Number   Territory Pricing

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

Albumin
    822 7134     $ [**]  
Alk Phos
    831 5459     $ [**]  
ALT
    808 3750     $ [**]  
Ammonia
    181 6842     $ [**]  
Amylase
    820 8191     $ [**]  
AST
    811 3979     $ [**]  
Calcium
    804 8191     $ [**]  
Cholesterol
    835 4888     $ [**]  
CK
    835 8582     $ [**]  
Creatinine
    818 3477     $ [**]  
ECO2
    853 8670     $ [**]  
Gamma GT
    826 1315     $ [**]  
Glucose
    813 0536     $ [**]  
LDH
    835 1082     $ [**]  
Lipase
    196 6191     $ [**]  
Magnesium
    108 0266     $ [**]  
Phosphorus
    807 0856     $ [**]  
Total Bilirubin
    838 0396     $ [**]  
Total Protein
    193 7093     $ [**]  
Triglycerides
    192 2285     $ [**]  
Urea Nitrogen
    150 7326     $ [**]  
Uric Acid
    100 0793     $ [**]  

                  Profile Slides (Box of 24)   Catalog Number   Territory
Pricing

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

General Health Profile
    160 7175     $ [**]  
Pre-Anesthetic Panel
    801 5109     $ [**]  
Large Animal Profile
    680 0071     $ [**]  

                  Other   Catalog Number   WW Pricing

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

Vetrols
    869 9852     $ [**]  
Tips
    175 7384     $ [**]  

35

--------------------------------------------------------------------------------

 

Schedule 6 – Minimum Prices for New Chemistries

36

--------------------------------------------------------------------------------

 

Schedule 7 - Illustrative Rebate Calculations

The Estimated Rebate Payments will be calculated for each of the first three
calendar quarters using the Effective Rebate Rate, as described more fully in
sub-clause 7.03 of the Agreement. Any required adjustments will be made at the
end of the fourth calendar quarter, in accordance with sub-clause 7.03 of the
Agreement.

Example: The aggregate Annual Purchase Forecast for IDEXX and IDEXX US in a
given year is [**] slides; pricing is $[**]/slide; blended rebate percentage
rate is [**]%, as follows:

      [**] slides * [**]% = [**] slides
[**] slides * [**]% = [**] slides
[**] slides * [**]% = [**] slides
[**] slides * [**]% = [**] slides
[**] slides * [**]% = [**] slides
Total Slides Eligible for Rebate = [**] slides

                Effective Rebate = Total slides eligible for rebate / total
purchases = [**] = [**]%

Actual aggregate volume purchased by IDEXX and IDEXX US equals volume projected
at the beginning of the year.

                                                      Actual Qtrly.            
      Calculated   [**]%             Vol.   Purchases   Effective Rebate  
Rebate Each Qtr.   Holdback   Rebate Paid     ([**])   ($[**])   % [**] Vol.)  
([**])   ([**])   ([**])    

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

1st Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
2nd Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
3rd Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
4th Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
 
    [**]     $ [**]             $ [**]     $ [**]     $ [**]  
 
                      True-up:   $ [**]             $ [**]  
 
                      Total:   $ [**]             $ [**]  
 
                           

--------------------------------------------------------------------------------

             

--------------------------------------------------------------------------------

 

Actual aggregate volume purchased by IDEXX and IDEXX US is greater than volume
projected at the beginning of the year.

                                                      Actual Qtrly.            
      Calculated   [**]%             Vol.   Purchases   Effective Rebate  
Rebate Each Qtr.   Holdback   Rebate Paid     ([**])   ($[**])   % 9[**] Vol.)  
([**])   ([**])   ([**])    

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

1st Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
2nd Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
3rd Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
4th Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
 
    [**]     $ [**]             $ [**]     $ [**]     $ [**]  
 
                      True-up:   $ [**]             $ [**]  
 
                      Total:   $ [**]             $ [**]  
 
                           

--------------------------------------------------------------------------------

             

--------------------------------------------------------------------------------

 

37

--------------------------------------------------------------------------------

 

Actual aggregate volume purchased by IDEXX and IDEXX US is lower than volume
projected at the beginning of the year.

                                                      Actual Qtrly.            
      Calculated   [**]%             Vol.   Purchases   Effective Rebate  
Rebate Each Qtr.   Holdback   Rebate Paid     ([**])   ($[**])   % [**] Vol.)  
([**])   ([**])   ([**])    

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

1st Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
2nd Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
3rd Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
4th Qtr
    [**]     $ [**]       [**] %   $ [**]     $ [**]     $ [**]  
 
    [**]     $ [**]             $ [**]     $ [**]     $ [**]  
 
                      True-up:   $ [**]             $ [**]  
 
                      Total:   $ [**]             $ [**]  
 
                           

--------------------------------------------------------------------------------

             

--------------------------------------------------------------------------------

 

Calculation of IDEXX’s Proportionate Share of rebate (assuming Actual aggregate
volume purchased by IDEXX and IDEXX US equals volume projected at the beginning
of the year):

Assumptions:

•   Number of slides purchased by IDEXX: [**] slides   •   Total number of
slides purchase by IDEXX and its affiliates: [**] slides   •   Total rebate
earned: $[**]

Calculation:

IDEXX’s rebate equals: [**] slides / [**] slides * $[**], or $[**].

38

--------------------------------------------------------------------------------

 

Schedule 8 – Eligible New Chemistry Slides

[**]

39

--------------------------------------------------------------------------------

 

\

Schedule 9 – Example of Cost Adjustment Calculations

(Assumes PPI = [**]%)

                                                                               
                      Scenario 1   Scenario 2                            

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

            % of OCD’s   Year 1   % Change   Year 2   $ Change   % Change   Year
2   $ Change Costs   Usage   Cost   In Cost   Cost   in Cost   in Cost   Cost  
in Cost

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 

--------------------------------------------------------------------------------

 
    [**]       [**] %   $ [**]       [**] %   $ [**]     $ [**]       [**] %   $
[**]     $ [**]  
 
    [**]       [**] %   $ [**]       [**] %   $ [**]     -$ [**]       [**] %  
$ [**]     $ [**]  
 
    [**]       [**] %   $ [**]       [**] %   $ [**]     $ [**]       [**] %   $
[**]     $ [**]  
 
    [**]       [**] %   $ [**]       [**] %   $ [**]     $ [**]       [**] %   $
[**]     $ [**]  
 
    [**]             $ [**]       [**]     $ [**]     $ [**]       [**]     $
[**]     $ [**]  
 
          Total   $ [**]       [**] %   $ [**]     $ [**]       [**] %   $ [**]
    $ [**]  
 
          Total (x[**])   $ [**]       [**] %   $ [**]     $ [**]       [**] %  
$ [**]     $ [**]  

Scenario 1 Conclusion: [**]Cost Adjustment Required (Other Costs Increased by <
[**]% over PPI)

         
Adjustment Calculation [**]:
       
Actual [**]
  $ [**]  
Less: PPI Change ([**]% of $[**])
  $ [**]  
Total Adjustment
  $ [**]  

Scenario 2 Conclusion: [**] Costs Adjustments Required

             
Adjustment Calculation [**]
         
Same as above
  $ [**]    
Adjustment for [**] Costs:
         
Actual Cost Change
  $ [**]    
Less: “PPI Plus [**]%” Change ([**]% *$[**])
  $ [**]    
Adjustment
  $ [**]    
Total Adjustment
  $ [**]  
 
   

--------------------------------------------------------------------------------

 

* - [**] Costs - [**] $[**], or $[**]/slide @ [**] slides

40

--------------------------------------------------------------------------------

 

Schedule 10 – Additional Countries in the Territory

      Albania   Liechtenstein Andorra   Lithuania Armenia   Macedonia Azerbaijan
  Malta Bahrain   Monaco Belarus   Norway Bosnia and Herzegovina   Oman Bulgaria
  Pakistan Croatia   Poland Cyprus   Qatar Czech Republic   Romania Estonia  
Russia Faroes Islands   San Marino Georgia   Saudi Arabia Hungary   Slovakia
Iceland   Slovenia Iran   Switzerland Iraq   Syria Israel   Tajikistan Jordan  
Turkey Kazakhstan   Turkmenistan Kuwait   Ukraine Kyrgyzstan   United Arab
Emirates Latvia   Uzbekistan Lebanon   Yemen

41